Dolby Laboratories, Inc. vs Intuitive Surgical, Inc. — how do they compare? Dolby Laboratories, Inc. trades at $60.69 (market cap $5.75B), while Intuitive Surgical, Inc. trades at $400.9 (market cap $141.75B). The key difference: Intuitive Surgical, Inc. is far larger — about 24.7× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| DLB | ISRG | |
|---|---|---|
Market Cap | $5.75B | $141.75B |
Sector | Industrials | Health |
52-Week High | $75.62 | $592.85 |
52-Week Low | $48.51 | $332.02 |
Enterprise Value | $5.12B | $136.53B |
Dividend Yield | 2.35% | — |
Signals from Pluang's Aura AI — not financial advice
DLB trades at $60.90, down 1.93% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company has consistently beaten EPS estimates in recent quarters, including Q2 2026 with $0.69 actual versus $0.67 expected. Revenue has been stable around $1.3B annually, with a strong gross profit margin of 87.61% in 2025. Analyst consensus is a Buy with a price target of $87.50, suggesting significant upside. Recent news highlights growth in Dolby Atmos and automotive licensing.
The outlook for DLB is positive, supported by strong fundamentals and analyst optimism, but near-term execution risks and licensing volatility pose challenges. The stock's current valuation metrics, including a P/E of 26.11, appear reasonable given growth prospects. Key risks include revenue fluctuations and competitive pressures in the audio-video sector.
Intuitive Surgical (ISRG) trades at $393.38, up 3.85% on the day, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The stock exhibits premium valuation metrics, including a P/E of 46.01 and P/S of 13.08, supported by robust revenue growth, which reached $10.06B in 2025, and high net income margins of 28.45%. Recent news highlights analyst upgrades and optimism around the da Vinci 5 system's adoption.
The outlook remains positive given durable demand and innovation, but risks include heightened competition and valuation sensitivity. Wall Street consensus is bullish with a $518.10 price target, implying significant upside, though investors should weigh premium multiples against growth sustainability and competitive pressures in the medtech space.
Trailing returns across standard periods
Latest headlines on both assets
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →